全文获取类型
收费全文 | 307篇 |
免费 | 9篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 16篇 |
妇产科学 | 13篇 |
基础医学 | 11篇 |
口腔科学 | 4篇 |
临床医学 | 24篇 |
内科学 | 51篇 |
皮肤病学 | 3篇 |
神经病学 | 6篇 |
特种医学 | 55篇 |
外科学 | 44篇 |
综合类 | 60篇 |
预防医学 | 11篇 |
药学 | 7篇 |
肿瘤学 | 10篇 |
出版年
2017年 | 2篇 |
2016年 | 7篇 |
2015年 | 2篇 |
2014年 | 8篇 |
2013年 | 5篇 |
2012年 | 7篇 |
2011年 | 2篇 |
2010年 | 4篇 |
2009年 | 15篇 |
2007年 | 5篇 |
2006年 | 11篇 |
2005年 | 5篇 |
2004年 | 4篇 |
2002年 | 6篇 |
2001年 | 7篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1998年 | 6篇 |
1997年 | 8篇 |
1996年 | 10篇 |
1995年 | 15篇 |
1994年 | 14篇 |
1993年 | 4篇 |
1991年 | 3篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 1篇 |
1986年 | 4篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 6篇 |
1982年 | 11篇 |
1981年 | 3篇 |
1980年 | 5篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1977年 | 3篇 |
1976年 | 1篇 |
1974年 | 2篇 |
1968年 | 1篇 |
1964年 | 1篇 |
1959年 | 7篇 |
1958年 | 10篇 |
1957年 | 21篇 |
1956年 | 19篇 |
1955年 | 12篇 |
1954年 | 15篇 |
1949年 | 7篇 |
1948年 | 2篇 |
1946年 | 1篇 |
排序方式: 共有316条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
Peripancreatic lymphoadenopathy and extrahepatic immunological manifestations in chronic hepatitis C 总被引:1,自引:0,他引:1
S. NERI C. M. BRUNO G. D'ANGELO S. RUSSO 《European journal of clinical investigation》1996,26(8):665-667
Abstract. The aim of the study was to determine the role of peripancreatic lymph node swelling in systemic immunological alterations during chronic hepatitis C (HC). The prospective study was carried out as a clinical study in a university hospital. Clinical, haematochemical and ultrasonographic findings in 182 patients were studied. Ultrasonography was performed by the same operator and the findings were evaluated blind without the operator knowing the clinical and haematochemical parameters. Hepatitis B virus (HBV) markers, anti-HCV antibodies. LKMl, cryoglobulinaemia, rheumatoid factor and anti-tissue antibodies were determined. Liver biopsy was carried out in 43 of the 182 patients. One or two pathological peripancreatic lymph nodes (PLNs) were present in 30 of the 182 patients and, of the 30, 28 were anti-HC positive. Only one patient in the non-PLN group was positive for anti-HCV, there being statistical significance ( P <0.0001) between the PLN and non-PLN groups. In HCV-positive patients, extrahepatic immunological manifestations were observed (cryoglobulinaemia; positivity to anti-smooth muscle, antinuclear and antimitochondrial antibodies; positivity to rheumatoid factor and LKMl). In five patients the presence of focal lymphocytic aggregates was detected by biopsy, whereas one patient presented typical ocular lesion of Mikulicz's syndrome. Our results may confirm the marked lymphotropism shown by the HC virus and indicate more complex immune system involvement, especially in view of the coexisting signs of immune system involvement related to the presence of intrahepatic cellular aggregates detected in our study. We believe that the peripancreatic adenopathy in chronic HCV hepatitis is an important diagnostic sign and may indicate an involvement of the C virus in the still unexplained extrahepatic immunological disorders. 相似文献
5.
6.
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma 总被引:1,自引:0,他引:1
M.R. VALERIO P. TAGLIAFERRI† F. RASPAGLIESI‡ F. FULFARO G. BADALAMENTI C. ARCARA G. CICERO A. RUSSO S. VENUTA† G. GUARNERI§ & N. GEBBIA 《International journal of gynecological cancer》2006,16(S1):79-85
Abstract. Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcara C, Cicero G, Russo A, Venuta S, Guarneri G, Gebbia N. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer 2006; 16(Suppl. 1): 79–85
We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m2 ), pegylated liposomal doxorubicin (30 mg/m2 ), and cyclophosphamide (750 mg/m2 ). A total of 49 patients (39 assessable for toxicity and response) were enrolled in this trial. Neutropenia grade 3 was observed in six patients (15%) and anemia grade 3 in one patient (0.2%). Fatigue grade 1–2 occurred in 26 patients (66%), nausea/vomiting grade 1 in 23 patients (58%), and alopecia grade 1–2 in 19 patients (48%). Twenty-one (53%) patients experienced grade 1–2 peripheral neuropathy. The overall response rate was 46% (95% CI 23.6–68.7). Median progression-free survival was 28 weeks (range 12–52 weeks) and median survival was 45 weeks (range 26–136+ weeks). The mean duration of response was 34 weeks (range 16–52 weeks). In platinum-resistant and -refractory ovarian cancer patients, the overall response rate was 37% (CI 95% 14.4–60.8) with a progression-free survival of 28 weeks (range 12–52 weeks) and a median survival of 42 weeks (range 28–84 weeks). This combination chemotherapy is generally well tolerated and is an active second-line regimen against ovarian cancer. 相似文献
We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m
7.
目的观察再发性低血糖后脑内葡萄糖转运蛋白1(glucose transporter 1,GLUT1)及葡萄糖转运蛋白3(GLUT3)表达的变化,从而探讨无症状低血糖的发生机制。方法将80只15日龄野生型小鼠随机分为正常对照组及低血糖组,每组40只。低血糖组给予正规胰岛素腹腔注射3次,每次剂量为5U/kg,对照组注射等体积生理盐水。两组分别在最后1次注射后12、24、48及72 h处死小鼠取脑组织(每组每时间点10只),应用免疫组化方法观察小鼠脑内GLUT1及GLUT3表达的变化。结果低血糖后脑内微血管上GLUT1表达有增加趋势,皮质增加高于海马,72 h皮质GLUT1表达显著高于对照组;低血糖后48、72 h皮质及海马GLUT3表达均显著高于相应对照组。结论再发性低血糖后脑内GLUT1及GLUT3适应性增高,这种适应既能节省神经元的能量代谢,但也能削减神经元对低血糖的反应。 相似文献
8.
Ventricular Tachycardia/Ventricular Fibrillation Ablation in the Setting of Ischemic Heart Disease 总被引:1,自引:0,他引:1
FRANCIS MARCHLINSKI M.D. FERMIN GARCIA M.D. AMIR SIADATAN M.D. WILLIAM SAUER M.D. STUART BELDNER M.D. ERICA ZADO P.A.-C. HENRY HSIA M.D. DAVID LIN M.D. JOSHUA COOPER M.D. RALPH VERDINO M.D. EDWARD GERSTENFELD M.D. SANJAY DIXIT M.D. REA RUSSO M.D. DAVID CALLANS M.D. 《Journal of cardiovascular electrophysiology》2005,16(S1):S59-S70
Recurrent ventricular tachycardia (VT) in the setting of coronary artery disease is frequently a life-threatening electrophysiologic emergency. Even in patients with an implantable defibrillator, recurrent VT is frequently accompanied by repeated and disabling shock therapy. Catheter ablative therapy offers the ability to provide immediate control of recurrent VT. Long-term elimination of VT should be anticipated in most patients. This article reviews the strategies, tools, techniques, and expected outcome for catheter ablation of stable and unstable ventricular arrhythmias in the setting ischemic heart disease. 相似文献
9.
GEMMA PELARGONIO MARIA L. NARDUCCI ELEONORA RUSSO MICHELA CASELLA PASQUALE SANTANGELI ROBERT CANBY AMIN AL‐AHMAD LARRY D. PRICE LUIGI DI BIASE CANDICE J. KWARK MARK HARWOOD FRANCESCO PERNA GIANLUIGI BENCARDINO CAROLINA IERARDI ENRICO M. TRECARICHI ENRICA SANTELLI MARIO TUMBARELLO PRASANT MOHANTY SHANE BAILEY JOHN DAVID BURKHARDT FULVIO BELLOCCI ANDREA NATALE ANTONIO DELLO RUSSO 《Journal of cardiovascular electrophysiology》2012,23(10):1103-1108
Transvenous Lead Extraction . Introduction: As the population ages, the number of elderly patients with implantable cardiac devices referred for transvenous lead extraction will dramatically increase in Western countries. The safety and effectiveness of lead extraction in elderly patients has not been well evaluated. We report the safety and effectiveness of transvenous lead extraction in octogenarians. Methods and Results: From January 2005 to January 2011, we reviewed data from consecutive patients ≥ 80 years referred to our institutions for transvenous lead extraction because of cardiac device infection or lead malfunction. Clinical characteristics, procedural features, and periprocedural major and minor complications were compared between octogenarians and younger patients. Out of 849 patients undergoing lead extraction in the participating institutions during the study period, 150 (18%) patients were octogenarians (mean age 84 years; range 80–96; 64% males). A significantly higher percentage of octogenarians presented with chronic renal failure (55% vs 26%; P < 0.001), history of malignancy (22% vs 6%; P < 0.001), and chronic obstructive pulmonary disease (46% vs 19%; P < 0.001). Complete lead extraction rates were similar in the 2 age groups (97% in octogenarians vs 96% in patients <80 years; P = 0.39). Periprocedural death occurred in 2 (1.3%) patients ≥80 years and in 5 (0.72%) patients <80 years (P = 0.45 for comparison). No differences in terms of other periprocedural major and minor complications were found between the 2 age groups. Conclusion: Despite presenting with a significantly higher rate of comorbidities, transvenous lead extraction can be performed safely and successfully in octogenarians. (J Cardiovasc Electrophysiol, Vol. 23 pp. 1103‐1108, October 2012) 相似文献
10.
In vivo release and turnover of secreted platelet antiheparin proteins in rhesus monkey (Macaca mulatta) 总被引:1,自引:0,他引:1
Musial J; Niewiarowski S; Edmunds LH Jr; Addonizio VP Jr; Nicolaou KC; Colman RW 《Blood》1980,56(4):596-607
Human and rhesus monkey platelets secrete at least two antiheparin proteins: platelet factor 4 (PF4) and low affinity platelet factor 4 (LA-PF4). Neither of these proteins showed species-related antigenic differences. As determined by radioimmunoassay, the levels of PF4 and LA-PF4 antigen per 10(9) monkey platelets amounted to 10.7 and 20.3 microgram, respectively. One milliliter of monkey plasma prepared from blood collected into an anticoagulant composed of EDTA, prostaglandin E1, and theophylline solution contained 22.4 ng LA-PF4 and 8.0 ng PF4. Concentrations of these two platelet-specific proteins in monkeys closely resembled levels found in human platelets and plasma. Infusion of prostacyclin (PGI2) (100 or 300 ng/kg/min) into monkeys for 15 min resulted in a significant decrease of plasma levels of LA-PF4 antigen and of PF4 by 40%--60% (p < 0.0001). This decrease was related to the inhibitory effect of PGI2 on the secretion of platelets stimulated by a catheter or by venipuncture. Longer infusion of PGI2 did not produce further significant change. The supernate obtained after aggregation of human platelets stimulated by thrombin was injected into monkeys receiving PGI2 infusion. The disappearance of LA-PF4 antigen in monkey plasma followed a biphasic exponential curve with half-lives for the fast and slow components of 8.4 and 63 min. PF4 disappeared faster but followed the same pattern (half-lives for the fast and slow component of 2.1 and 70 min). Analysis of the experimental data suggests that the low levels of secreted platelet proteins in monkey plasma are related to their minimal in vivo release and to their rapid clearance. 相似文献